Immunocore Holdings (IMCR) Gains from Investment Securities (2019 - 2026)
Immunocore Holdings' (IMCR) quarterly Gains from Investment Securities came in at $13000.0 in Q1 2026, down 59.38% year-on-year from $32000.0 in Q1 2025, and up 100.23% quarter-over-quarter from -$5.7 million in Q4 2025.
Immunocore Holdings (IMCR) Gains from Investment Securities (2019 - 2026) Analysis & Trends
Immunocore Holdings has disclosed Gains from Investment Securities across 8 years of filings, most recently posting $13000.0 for Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $13000.0, down 59.38% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.1 million (down 630.35% YoY), and the FY2025 annual result was -$2.1 million, down 514.31% from the prior year.
- Gains from Investment Securities came in at $13000.0 for Q1 2026 at Immunocore Holdings, up from -$5.7 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $4.6 million in Q3 2025 to a low of -$5.7 million in Q4 2025.
- The 5-year median for Gains from Investment Securities is $149000.0 (2024), against an average of $96273.7.
- Peak annual rise in Gains from Investment Securities reached 1481.57% in 2025, while the deepest fall reached 3706.33% in 2025.
- Immunocore Holdings' Gains from Investment Securities stood at $1.8 million in 2022, then sank by 57.19% to $757000.0 in 2023, then tumbled by 79.13% to $158000.0 in 2024, then plunged by 3706.33% to -$5.7 million in 2025, then soared by 100.23% to $13000.0 in 2026.
- The last three Gains from Investment Securities figures came in at $13000.0 (Q1 2026), -$5.7 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - |
| 2 | Belite Bio | 55,234.00 Bn | 55,234.00 Bn | - |
| 3 | Quantum Biopharma | 17,823.14 Bn | 17,823.14 Bn | - |
| 4 | Legend Biotech | 3,624.50 Bn | 3,624.21 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,745.73 Bn | 1,745.73 Bn | - |
| 6 | Evaxion A | 1,540.85 Bn | 1,540.84 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.57 Bn | 105.33 Bn | 2.59 Bn |
| 9 | Abivax | 93.46 Bn | 93.46 Bn | - |
| 10 | Immunocore Holdings | 1.46 Bn | 616.35 Mn | 106.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13,000.00 |
| Mar 31, 2026 | 13,000.00 |
| Dec 31, 2025 | -5.70 Mn |
| Dec 31, 2025 | -5.70 Mn |
| Sep 30, 2025 | 4.63 Mn |
| Sep 30, 2025 | 4.63 Mn |
| Jun 30, 2025 | -1.08 Mn |
| Jun 30, 2025 | -1.08 Mn |
| Mar 31, 2025 | 32,000.00 |
| Mar 31, 2025 | 32,000.00 |
| Dec 31, 2024 | 158,000.00 |
| Dec 31, 2024 | 158,000.00 |
| Sep 30, 2024 | 293,000.00 |
| Sep 30, 2024 | 293,000.00 |
| Jun 30, 2024 | -81,000.00 |
| Jun 30, 2024 | -81,000.00 |
| Mar 31, 2024 | 140,000.00 |
| Mar 31, 2024 | 140,000.00 |
| Dec 31, 2023 | 757,000.00 |
| Dec 31, 2023 | 757,000.00 |